



International Journal of Pharmacology and Clinical Research (IJPCR)

IJPCR | Vol.9 | Issue 4 | Oct - Dec -2025

www.ijpcr.net

ISSN: 2349-5448

DOI : <https://doi.org/10.61096/ijpcr.v9.iss3.2025.709-718>



Research

ANTIDIABETIC ACTIVITY OF METHANOLIC EXTRACTS OF LEAVES OF SOLANUM PUBESCENS WILLD ON ALLOXAN INDUCED DIABETIES IN RATS

Pandula Vijayakanth^{1*}, Dr.I. Harikiran²

^{1,2} Department Of Pharmacology, Princeton College Of Pharmacy In Narapally, Ghatkesar, Telangana.

*Corresponding Author: Pandula Vijayakanth
Email: princeton.pharmacy@gmail.com

	Abstract
Published on: 17.11.2025	<p>Solanum pubescens Willd., belongs to the family Solanaceae, have pharmacological actions like hepatoprotective, gastroprotective, anti-inflammatory, antimicrobial, antihelmethic.</p>
Published by: Futuristic Publications	<p>Objetive: To investigate antioxidant activity of methanolic leaf extract of Solanum pubescens Willd., on alloxan induced diabetic rats.</p>
<p>2025 All rights reserved.</p>  <p>Creative Commons Attribution 4.0 International License.</p>	<p>Methods: Alloxan is administered as an inducer for diabetes. Thirty Wistar albino rats were randomly divided into five groups. Either sex of Wister strains of albino rats were divided in to 5 groups were Group 1 served as normal control, Group 2 served as alloxan control, Group 3 were administered with standard drug (Glibenclamide), Group 4 and Group 5 were administered to different doses of methanolic extract of Solanum pubescens Willd., (i.e. 200 and 300 mg/kg/Kg body weight).The anti-diabetic activity was determined by glucometer in both normal and alloxan-induced diabetic rats. The methanolic extract of <i>Solanum Pubescens</i> showed significant reduction in blood glucose levels due to the presence of phytochemicals such as alkaloids in extracts.</p> <p>Results: Altered levels of the FBGL and OGTT in alloxan induced rats were brought back to normal on treatment with methanolic extract of Solanum pubescens Willd., Thus the positive results suggest that <i>solanum Pubescens</i> extract should be further studied to determine the bioactive chemical compounds as well as to understand the possible mechanism of action and evaluate their toxicity looking towards pharmaceutical actions.</p> <p>Conclusion: It was concluded from the result that the methanolic extract of Solanum pubescens Willd., showed significant antidiabetic activity in a dose dependent manner.</p> <p>Keywords: Solanum pubescens Willd., Antidiabetic activity, Glibenclamide, FBGL and OGTT.</p>

INTRODUCTION

1.1-Diabetes Mellitus (DM):

Diabetes is one of the most common non-communicable diseases and a serious life-long condition appearing worldwide. The etiology of diabetes is a complex interaction of genetic and environmental factors. It is a heterogeneous group of metabolic disorders characterized physiologically by dysfunction of pancreatic beta cells and deficiency in insulin secretion or insulin activity and clinically by hyperglycemia or impaired glucose tolerance and other manifestable disorders. It is an endocrinological syndrome abnormally having high levels of sugar in the blood. This may be either due to insulin not being produced at all, is not made at sufficient levels, or is not as effective as it should be.

Diabetes is still a serious health problem all over the world since it is associated with increased morbidity and mortality rate. When compared with the general population, mortality and morbidity increase in diabetes is mainly due to the associated chronic complications both specific (microvascular) and nonspecific (macrovascular). Since the disease prevails in both genders and in all age groups, the general public has a concern about its control and treatment¹.

1.2-Classification of DM

Diabetes is classified by underlying cause. The most common forms of diabetes are categorized as **Type 1**, or insulin-dependent diabetes mellitus (IDDM) - an autoimmune disease in which the body's own immune system attacks the pancreatic beta cells, rendering it unable to produce insulin and

Type 2, or non-insulin-dependent diabetes mellitus (NIDDM) - in which there is resistance to the effects of insulin or a defect in insulin secretion.

Type 2 diabetes commonly occurs in adults associated with obesity. There are many underlying factors that contribute to the high blood glucose levels in these individuals. An important factor is the resistance to insulin in the body essentially ignoring its insulin secretions. A second factor is the decreased production of insulin by the cells of the pancreas. Therefore, an individual with Type 2 diabetes may have a combination of deficient secretion and deficient action of insulin. In contrast to Type 2 diabetes, Type 1 diabetes most commonly occurs in children and is a result of the body's immune system attacking and destroying the beta cells. The trigger for this autoimmune attack is not clear, but the result is the end of insulin production².

Multiple risk factors for the development of Type 2 diabetes mellitus³:

- Family history (parents with diabetes).
- Obesity (i.e., $\geq 20\%$ over ideal body weight or body mass index $\geq 25\text{kg/m}^2$).
- Habitual physical inactivity.
- Impaired glucose tolerance.
- Hypertension ($\geq 140/90\text{mm Hg}$ in adults).
- High density lipoprotein (HDL) cholesterol $\leq 35\text{mg/dl}$ and/or triglyceride level $\geq 250\text{mg/dl}$.

1.3-History

The term "Diabetes" was first used around 250 B.C. It is a Greek word meaning "to syphon", reflecting how diabetes seemed to rapidly drain fluid from the affected individual. The Greek physician Aretaeus noted that affected individuals passed increasing amounts of urine as if there was "liquefaction of flesh and bones into urine". The complete term "diabetes mellitus" was coined in 1674 by Thomas Willis. Mellitus is Latin for honey, which is how Willis described the urine of diabetics⁵.

Historical accounts reveal that as early as 700-200 BC, diabetes mellitus was a well recognized disease in India and was even distinguished as two types, a genetically based disorder and other one resulting from dietary indiscretion. Ancient Hindu writings document how black ants and flies were attracted to the urine of diabetics. The Indian physician Sushruta in 400 B.C. described the sweet taste of urine from affected individuals, and for many centuries to come, the sweet taste of urine was a key to the diagnosis.

Physicians have observed the effects of diabetes for thousands of years. One of the effects of diabetes is the presence of glucose in the urine (glucosuria). For much of the time, little was known about this fatal disease that caused weight loss of body, extreme thirst, and frequent urination. It was in 1922 that the first patient was successfully treated with insulin. Till the mid-1800s, the treatments offered for diabetes varied tremendously. A breakthrough in the puzzle of diabetes came in 1889. German physicians Joseph von Mering and Oskar Minkowski surgically removed the pancreas from dogs. The dogs immediately developed diabetes. Now that a

link was established between the pancreas and diabetes, research focused on isolating the pancreatic extract that could treat diabetes. Dr. Frederick Banting succeeded in his experiments of isolating a pancreatic extract. The diabetic dog was kept alive for eight days by regular injections until supplies of the extract, at that time called "isletin", was exhausted. Experiments on dogs showed that extracts from the pancreas caused a drop in blood sugar, caused glucose in the urine to disappear, and produced a marked improvement in clinical condition.

A young boy, Leonard Thompson, was the first patient to receive insulin treatment in the year 1922 and lived for thirteen years. Over the next 70 years, insulin was further refined and purified. A revolution came with the production of recombinant human DNA insulin in 1978. Instead of collecting insulin from animals, new human insulin could be synthesized. In 1923, Banting and Macloed were awarded the Nobel Prize for the discovery of insulin. In his Nobel Lecture, Banting concluded the following about their discovery: "Insulin is not a cure for diabetes; it is a treatment."

2. MATERIALS AND METHODS

The designing of methodology involves a series of steps taken in a systematic way in order to achieve the set goal(s) under the prescribed guidelines and recommendations. It includes in it all the steps from field trip to the observation including selection and collection of the medicinal plant, selection of dose value, standardization of protocol, usage of instruments, preparation of reagents, selection of specific solvents for extraction, formation of protocols and final execution of the standardized protocol. All this requires good build of mind and a good and soft technical hand to handle the materials and procedure in a true scientific manner.

2.1 Drugs and Chemicals

Drugs and Chemicals used in this study were of analytical grade and of highest purity procured from standard commercial sources in India.

Table 1: Drugs and Chemicals

<i>S.No</i>	<i>Materials</i>	<i>Company Name</i>
1.	Alloxan	Quali Kems Fine Chem Pvt, Ltd, Vadodara.
5.	Methanol	ChangshuYangyuan Chemicals, China.
6.	Glibenclamide	Sanofi India Ltd, Ankleshwar.

2.2. Instruments

Following instruments were required for the study:

Table 2: List of Instruments used for study

<i>Name of the instrument</i>	<i>Source</i>
Centrifuge	Dolphin
Digital weighing balance	Horizon
Glucometer	Horizon
Heating mantle	ASGI®
Refrigerator	Videocon
Soxhlet extractor	ASGI®
Condenser	ASGI®
Burette stand	Dolphin
Round bottom flask	ASGI®, Amar
Mixer	Videocon
Oven	ASGI®
Water bath	ASGI®
Stirrer/glass rod	ASGI®
Watch glass	ASGI®
Whatmann filter paper	Manipore microproducts, Ghaizabad.
Butter paper	ASGI®
Spatula	ASGI®
Rubber pipes	ASGI®

2.3. Experimental animals

Healthy adult albino wistar rats weighing 200-250grams of either sex were selected for the study. Animals were housed in appropriate cages in uniform hygienic conditions and fed with standard pellet diet (Amrul Laboratory Animal Diet) and water ad libitum. They were fasted overnight before the day of experiment, after 72hours of fasting from the day of Alloxan introduction. Animals were housed within the departmental animal house and the room temperature was maintained at 27° C. Animal studies had approval of IAEC.

2.4. Plant Material Collection

The leaves of *Solanum pubescens* was collected from the ----- in the month of ----- and was identified and authenticated from Department of ----- .The plant material was cleaned, reduced to small fragments, air dried under shade at room temperature and coarsely powdered in a mixer. The powdered material was stored or taken up for extraction process.

2.5. Preparation of plant extracts:

Preparation of methanolic Extract:

Fresh leaves of *S.Pubescens* were collected and washed under tap water. The leaf extract used was prepared by taking 20gms of finely cut leaves into 250ml beaker containing 200ml of methanol. The contents were mixed well and then the mixture was boiled upto 50-60°C for 4-5hrs. Further the extract was filtered with whatmann filter paper. The filtrate was boiled until the concentrated residue is formed. The concentrated product was sealed in sample covers and stored under room temperature and used for further experiment to check the activities.

2.6. Selection of dose for animal study

The dose considered for the experiment on rats was obtained from conversion of human dose of *Solanum Pubescens* (3-5 g/kg). The conversion factor of human dose (per 200 g body weight) is 0.018 for rats and 0.002 for mice (Ghosh 1984). Hence the calculated dose for the rats (considering human dose 3 and 5 g/kg) is 200 and 300 mg/kg. Acute toxicity was done at dose of 2000mg/kg body weight.

2.7. Pharmacological evaluation

Preparation of extracts:

The aqueous and alcoholic extracts of *Solanum Pubescens* suspended in water in presence of 3%v/v Tween-80 solution. All the drugs were administered orally for experimental purpose. Each time preparations of the extracts were prepared when required. The drugs were administered at a constant volume of 10ml/kg for each animal.

2.8. ACUTE ORAL TOXICITY:

The acute oral toxicity of methanolic extracts of *Solanum kmpubescens* was determined by using Albino wistar rats (200-250g) which were maintained under standard conditions. The animals were fasted 12 hour prior to the experiment, up and down procedure OECD guideline no. 425 were adopted for toxicity studies. Animals were administered with single dose of individual extract upto 2000mg/kg and observed for its mortality during 2days and 7days study period (short term) toxicity and observed upto 7days for their mortality, behavioral and neurological profiles.

2.9. Assessment of Anti-diabetic Activity in Normal and Alloxan induced Rats

2.9.1 Assessment of hypoglycemic activity on normal rats.

Group Classification:

Group	Treatment	Dose(mg/kg)
Group 1	Normal control received distilled water	10ml/kg
Group 2	Standard group received Glibenclamide	10ml/kg
Group 3	Methanolic extract of <i>S.Pubescens</i>	200
Group 4	Methanolic extract of <i>S.Pubescens</i>	300

Procedure:

Animals were grouped and divided randomly into four groups of four and each was fasted to overnight. The blood samples were withdrawn by tail vein at 0 hour i.e. before I.P administration of extracts/standard/vehicle. Then blood was collected at an interval of 1, 2, 4, and 8 hour after the administration, and according to procedure blood glucose levels were measured by glucometer (ONE TOUCH glucometer). The administration of drug was continued upto fifteen days.

➤ **Oral glucose tolerance test(OGTT) in normal rats:**

On the next day (16th day) after the assessment of hypoglycemic activity OGTT was carried out in same normal animals.

Procedure:

All the animals in each group were administered 2g/kg of glucose one hour after extract/ glibenclamide/ vehicle administration. The blood samples were collected by tail vein at 0 hour, 0.5 hour, 1 hour, 1.5 hour and 2 hour after the administration of glucose load. Blood glucose levels were measured by glucometer.

2.9.2 Assessment Of Anti-Diabetic Activity In Alloxan Induced Diabetic Rats:**Induction of Diabetes:**

Albino wistar rats of either sex weighing 200-250 g were selected for the study. All the animals were allowed free access to water and pellet diet and maintained at room temperature in rat cages.

Alloxan was dissolved in normal saline immediately before use. Diabetes was induced in 16 hour fasted rats by single intraperitoneal injection of 120 mg/kg body weight of freshly prepared alloxan in normal saline.

The rats after alloxanization were given 5% w/v glucose solution in feeding bottles for next 24 hours in their cages to prevent hypoglycemia. After 72 hours rats with fasting blood glucose levels greater than 200 mg/dl were selected and used for further studies

All the animals were observed for seven days for consistent hyperglycemia (fasting blood glucose level greater than 200 mg/dl and lesser than 400 mg/dl) and such animals were selected and divided into six groups of four each and used for the study of the following experimental models.

Group Classification:

Group	Treatment	Dose(mg/kg)
Group 1	Normal control received distilled water	10ml/kg
Group 2	Diabetic control received distilled water	10ml/kg
Group 3	Standard group received Glibenclamide	10ml/kg
Group 4	Methanolic extract of <i>S.Pubescens</i>	200
Group 5	Methanolic extract of <i>S.Pubescens</i>	300

2.9.3 Effect of Methanolic extracts of *S.Pubescens* on blood glucose levels in alloxan induced diabetic rats:

All the animals of above groups were administered as per treatment protocol mentioned above. The blood samples were collected by retro orbital puncture at 0,1,2,4 and 8 hour after the administration. The treatment was continued for next 22 days. Again blood samples were also collected on 4th, 7th, 14th and 21st day after 1 hour administration for sub acute study. Blood glucose level was estimated at various time intervals by subjecting the collected blood to cold centrifugation for serum separation. Serum obtained was used for estimating glucose level using GOD/POD (span) kit.

Oral glucose tolerance test (OGTT) in alloxan induced diabetic rats:

On the 8th, 15th and 22nd day OGTT was carried out on the same alloxan induced diabetic animals used for assessment of anti-diabetic activity studies.

Procedure:

All the animals in each group were administered 2g/kg of glucose one hour after extract/ Glibenclamide/ vehicle administration. The blood samples were collected by retro orbital puncture at 0 hour, 0.5 hour, 1 hour, 1.5

hour and 2 hour after the administration of the glucose load. Serum was treated with solutions of GOD/POD kit and according to procedure blood glucose levels were measured under by Biochemical analyzer.

2.10. Statistical analysis

The values were expressed as mean \pm SEM data was analyzed using one-way ANOVA followed by T-test. Two sets of comparison had made. i.e.

1. Normal control Vs All treated groups.

2. Diabetic Control Vs All treated groups.

Differences between groups were considered significant at $P < 0.001$ and $P < 0.05$ levels.

RESULTS

Acute toxicity testing

Acute toxicity studies revealed that the alcoholic extracts of *Solanum Pubescens* were safe up to 2000 mg/kg of body weight and approximate LD 50 is more than 2000 mg/kg. No lethality or any toxic reactions was observed up to the end of the study period.

ANTI-DIABETIC ACTIVITY IN ALLOXAN INDUCED DIABETIC RATS

Fasting blood glucose levels (FBGL) in normal rats were in range of 90-100 mg/dl. Treatment with alloxan (120 mg/kg, I.P.) had increased the FBGL to range of 252-266 mg/dl after 72 hours. These values on subsequent days got stabilized by day seven on an average between 255 mg/dl.

Changes in the fasting blood glucose levels in different groups are tabulated in Table No: ----. This data shown that blood glucose level of normal control animals has maintained throughout the study period.

The group 1 which is the diabetic control group has shown significant increase in fasting blood glucose levels during this 21st day study period.

The group 2 Glibenclamide (10mg/kg) treated group has shown ($p < 0.005$) significant decrease in fasting blood glucose level during 7th, 14th and 21st day of study period.

Effect of MESP on antidiabetic activity in alloxan induced diabetic rats

The animals treated with 200 and 300 mg/kg of MESP shown significant decrease ($P < 0.005$) in FBGL on 7th, 14th and 21st day of treatment when compare to other groups of animals. These extract have reduced more (%) in FBGL when compared to control group. The detailed results are summarized in TableNo: ----

Table 3: Effect of MESP on fasting blood glucose level (FBGL) in Alloxan induced diabetic rats.

Treatment	Dose(mg/kg)	Blood glucose level(mg/dl)			
		0 day	7 th day	14 th day	21 st day
Normal control	-	100 \pm 1	100 \pm 1	96 \pm 1	97 \pm 2
Diabetic control	10	253 \pm 2	256 \pm 3	264 \pm 2	271 \pm 1
Glibenclamide	10	98 \pm 1	96 \pm 3	80 \pm 1	72 \pm 2
MESP	200	85 \pm 2	84 \pm 1	72 \pm 2	60 \pm 1
MESP	300	91 \pm 2	87 \pm 2	83 \pm 2	73 \pm 1

Values are expressed as mean \pm S.E.M. n=3. Significant values were compared with $P < 0.005$. Normal control Vs all groups. Paranthesis indicates % reduction in BGL.

Oral glucose tolerance test (OGTT) on 16th day-

MESP (200 and 300 mg/kg) significantly ($P < 0.005$) suppress the rise in FBGL after glucose load (2g/kg) in rats, at first half-an-hour and upto 2hr time period as compare with other groups extract glibenclamide on 15th day. While MESP produced significant reduction in FBGL. Glibenclamide (10mg/kg) showed ($P < 0.005$) significant suppression in FBGL rise at 1st, 8th, 15th & 22nd day normalized FBGL within 2hr. The detailed results are summarized in TableNo: ----.

Table 4: Effect of extracts of *S.Pubescens* on 22nd day in normal rats.

Traetment	Dose (mg/kg)	Blood glucose level(mg/dl)			
		1 st day	8 th day	15 th day	22 nd day
Normal control	-	101 \pm 2	142 \pm 4	132 \pm 2	118 \pm 2

Diabetic control	10	259±3	383±5	339±2	290±2
Std(Glibenclamide)	10	107±2	125±2	115±2	112±1
MESP	200	266±1	257±4	194±2	140±1
MESP	300	199±2	168±3	158±1	121±4

Values are expressed as mean \pm S.E.M. n=3. Significant values were compared with P<0.005. Normal control Vs all groups. Paranthesis indicates % reduction in BGL.

DISCUSSION

The present study was aimed at discovering the antidiabetic activity of methanolic extracts of *solanum Pubescens* at a dose of 200 and 300 mg/kg showed significant effect on glucose tolerance and the extracts also showed reduction in fasting blood glucose levels in normal and alloxan induced diabetic rats. These findings indicate that the extracts might be producing hypoglycaemic effect by a mechanism independent from the insulin secretion e.g. by the inhibition of endogenous glucose production or by the inhibition of intestinal glucose absorption. Alloxan monohydrate is one of the chemical agents used to induce diabetes mellitus in animals. It induces diabetes by dose dependent destruction of β -cells of islets of langerhans. It is a generator of free radicals of oxygen which cause extensive DNA damage. It was observed that single intravenous dose of alloxan exhibited significant hyperglycemia. Excessive hepatic glycogenolysis and gluconeogenesis associated with decreased utilization of glucose by tissues is the fundamental mechanism underlying hyperglycemia in the diabetic state. As the hyperglycemia induced by alloxan falls under category of mild diabetes and may reverse after a few weeks, the hypoglycemic effect of the plant in hyperglycemic rats was studied during 22 days treatment. The difference observed between the initial and final fasting blood glucose levels of extract treated hyperglycemic rats revealed antihyperglycemic effect of *solanum Pubescens* throughout the period of study. The effect of methanolic extracts of *solanum Pubescens* is compared with that of reference standard, Glibenclamide and it has shown a significant results.

SUMMARY

1. The fresh leaves of *Solanum Pubescens willd* used for this project work were procured locally.
2. The dried leaves of *Solanum Pubescens willd* were successively extracted with alcohol. Percentage yield was calculated.
3. Therapeutic dose of the extracts were calculated after carrying acute oral toxicity studies in rats.
4. Extracts were tested for their anti-diabetic activity in alloxan induced diabetic rats. OGTT also performed after repeated administration.
The following parameters were assessed:
 - fasting blood glucose levels
At 0, 7th, 14th and 21st day in alloxan induced diabetic rats.
5. Methanolic extracts of *Solanum Pubescens willd* (200 and 300 mg/kg) showed significant effect in blood glucose lowering activity and improved oral glucose tolerance test (OGTT) in short term (7th day) and long term (14th and 21st day) repeated administration in alloxan induced diabetic rats.
6. The above studies showed that Alcoholic extracts of *Solanum Pubescens willd* had potent anti-diabetic activity on repeated administration.

CONCLUSION

In current scenario, herbs are the potent sources of medicines used in the treatment of various disease and disorders. Since, plants are used as medicine there is prompt need of evaluation of plant species, therefore, the present work was conceived to evaluate the phytochemical and pharmacological screening of few Indian medicinal plants.

The Pharmacognostical evaluation of Indian medicinal plants viz., *Solanum Pobescenes* studied which include the morphological and physicochemical studies. The morphological studies of species plant part were studied which will be beneficial for the validation and assessment of quality control parameters of these plants to find out the presence of adulterant if any in order to establish the quality, safety and efficacy.

The data of the blood glucose level of rats treated with Alloxan (150mg/kg body weight) produced diabetes within 72 hours. After 72 hours of Alloxan administered the blood glucose levels of rats were observed. It was observed that significant lowering of sugar in alcoholic extract. The administration of MESP at a dose of

200 and 300 mg/kg showed significant anti-hyperglycaemic effect at 21st day which was evident from the 1st day onwards as compared to standard. The alcoholic extract of three extracts combination has showed better efficacy than the individual extract in all the treated extract. The anti-hyperglycaemic effect of the extract on the fasting blood sugar levels on diabetic rats is shown in table. The decreasing blood glucose levels are comparable with that of 10 mg/kg of Glibenclamide. The Glibenclamide (10 mg/kg body weight) shows significant effect on compare to the initial and more significant effect on the 7th Day compare to the initial. The methanolic extracts (200mg/kg body weight) shows significant ($P < 0.01$), effect.

Results of anti-diabetic activity of extracts established the scientific basis for the utility of these plants in the treatment of diabetes. The methanolic extracts have shown significant reduction in blood glucose levels in alloxan induced diabetic rats and produced maximum anti-diabetic activity and are higher than the hypoglycaemic activity of Glibenclamide in the diabetic rats. Therefore it is obvious that the fractionation with alcohol has enriched the active principles. In glucose loaded animals, the drug has reduced the blood glucose to the normal levels. It is possible that the drug may be acting by potentiating the pancreatic secretion or increasing the glucose uptake. Alcoholic extracts in combination has reduced the glucose levels, in prolonged treatment study. In conclusion, these extract showed significant anti-diabetic effect in diabetic rats after oral administration. Thus the claim made by the traditional Indian systems of medicine regarding the use of these plants in the treatment of diabetes stands confirms.

ACKNOWLEDGEMENT

The Authors are thankful to the Management and Principal, Princeton College of Pharmacy, Narapally, Ghatkesar, Telangana, for extending support to carry out the research work. Finally, the authors express their gratitude to the Sura Pharma Labs, Dilsukhnagar, Hyderabad, for providing research equipment and facilities.

BIBLIOGRAPHY

1. Consultation, W. H. O. *Definition, diagnosis and classification of diabetes mellitus and its complications*. Vol. 1. Part. 1999.
2. Alberti, Kurt George Matthew Mayer, and PZ ft Zimmet. "Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation." *Diabetic medicine* 15.7 (1998): 539-553.
3. Gress, Todd W., et al. "Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus." *New England Journal of Medicine* 342.13 (2000): 905-912.
4. Ahmed, Awad M. "History of diabetes mellitus." *Saudi medical journal* 23.4 (2002): 373-378.
5. Zimmet, Paul Z., Daniel J. McCarty, and Maximilian P. de Courten. "The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome." *Journal of Diabetes and its Complications* 11.2 (1997): 60-68.
6. American Diabetes Association. "Type 2 diabetes in children and adolescents." *Pediatrics* 105.3 (2000): 671-680.
7. Saltiel, Alan R., and C. Ronald Kahn. "Insulin signalling and the regulation of glucose and lipid metabolism." *Nature* 414.6865 (2001): 799-806.
8. Browning, Jeffrey D., and Jay D. Horton. "Molecular mediators of hepatic steatosis and liver injury." *Journal of Clinical Investigation* 114.2 (2004): 147-152.
9. Aronoff, Stephen L., et al. "Glucose metabolism and regulation: beyond insulin and glucagon." *Diabetes Spectrum* 17.3 (2004): 183-190.
10. Ross, E. J., and D. C. Linch. "Cushing's syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis." *The Lancet* 320.8299 (1982): 646-649.
11. Levin, Marvin E., Vincenza C. Boisseau, and Louis V. Avioli. "Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes." *New England Journal of Medicine* 294.5 (1976): 241-245.
12. Sherwin, Robert, and Philip Felig. "Pathophysiology of diabetes mellitus." *The Medical clinics of North America* 62.4 (1978): 695-711.
13. Faber, O. K., and C. Binder. "C-peptide response to glucagon: a test for the residual β -cell function in diabetes mellitus." *Diabetes* 26.7 (1977): 605-610.
14. Ioannidis, Ioannis. "Pathophysiology of Type 1 diabetes." *Diabetes in Clinical Practice: Questions and Answers from Case Studies* 31 (2007): 23.
15. Scheen, A. J. "Pathophysiology of type 2 diabetes." *Acta Clinica Belgica* 58.6 (2003): 335-341.
16. Vambergue, A., et al. "[Pathophysiology of gestational diabetes]." *Journal de gynécologie, obstétrique et biologie de la reproduction* 31.6 Suppl (2002): 4S3-4S10.
17. Inzucchi, Silvio E. "Diagnosis of diabetes." *New England Journal of Medicine* 367.6 (2012): 542-550.

18. Turner, R. C., et al. "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)." *lancet* 352.9131 (1998): 837-853.
19. Brownlee, M., and A. Cerami. "The biochemistry of the complications of diabetes mellitus." *Annual review of biochemistry* 50.1 (1981): 385-432.
20. Pari, L., and G. Saravanan. "Antidiabetic effect of Cogent db, a herbal drug in alloxan-induced diabetes mellitus." *Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology* 131.1 (2002): 19-25.
21. Day, Caroline. "Traditional plant treatments for diabetes mellitus: pharmaceutical foods." *British Journal of Nutrition* 80.01 (1998): 5-6.
22. Smith, George Davey, et al. "Genetic epidemiology and public health: hope, hype, and future prospects." *The Lancet* 366.9495 (2005): 1484-1498.
23. Hemamalini, K., et al. "Gastroprotective Activity of Gymnosporia emerginata, Solanum pubescence and Anogessius acuminate Leaf Extract against Ethanol-induced Gastric mucosal injury in Rats." *International Journal of Pharmaceutical and Biomedical Research* 2.1 (2011): 38-42.
24. Rahman, Haseeb Ur, et al. "PHYTOCHEMICAL PROFILING OF SUCCESSIVE EXTRACTS OF FRUIT AND STEM BARK OF SOLANUM PUBESCENS." *International Journal of Pharmacy and Pharmaceutical Sciences* 6.9 (2014).
25. SUMALATHA, PEDDI, K. HEMAMALINI, and M. VIJUSHA. "ANTI OXIDANT PROPERTY METHANOLIC EXTRACT OF Solanum pubescens Willd., ON PARACETAMOL INDUCED OXIDATIVE STRESS IN ALBINO RATS."
26. HEMAMALINI, K., and A. SAMBASIVA RAO. "ANTI ULCEROGENIC MODELS OF SOPHORA INTERRUPTA SOLANUM PUBESCENS AND TABEBUIA ROSEA LEAVES ON INVIVO TEST MODEL IN RATS." *International Journal of Pharmacy & Pharmaceutical Sciences* 6.6 (2014).
27. Rahman, Haseeb Ur, et al. "PHYTOCHEMICAL PROFILING OF SUCCESSIVE EXTRACTS OF FRUIT AND STEM BARK OF SOLANUM PUBESCENS." *International Journal of Pharmacy and Pharmaceutical Sciences* 6.9 (2014).
28. Hemamalini, K., et al. "Gastroprotective Activity of Gymnosporia emerginata, Solanum pubescence and Anogessius acuminate Leaf Extract against Ethanol-induced Gastric mucosal injury in Rats." *International Journal of Pharmaceutical and Biomedical Research* 2.1 (2011): 38-42.
29. Pushpalatha, M., and T. Ananthi. "Protective Effect of SolanumpubescensLINN on CCl4Induced Hepatotoxicity in Albino Rats." *Mintage Journal of Pharmaceutical and Medicinal Science* 1.1 (2012): 11-13.
30. Hemamalini, K., and Anurag Bhargava. "Preclinical efficacy and safety of herbal formulation for management of wounds." *International Journal of Pharmaceutical Science and Research* 4.9 (2013): 3466-3470.
31. Bhargav, Anurag, Et Al. "Antidiarrheal Activity Of Methanolic Extract Of Leaves Of Solanum Pubescenswilld And Gymnosporia Emerginata." *Asian Journal Of Pharmaceutical And Clinical Research* 5.3 (2012): 226-227.
32. Sharath, Goud t. "In-Vitro Anthelmintic Activity Of Solanam Pubescens And Gymnosporia Emerginata Leave."
33. Bhaargavi, Vuyyuri, G. S. L. Jyotsna, and Reshma Tripurana. "A REVIEW ON HEPATOPROTECTIVE ACTIVITY." *International Journal of Pharmaceutical Sciences & Research* 5.3 (2014).
34. ON, ANTIAMNESIC ACTIVITY OF GUGGUL EXTRACT, and ALBINO WISTAR RATS. "International Journal of Pharmacy."
35. Schmidt, Adam, et al. "Polymethylated myricetin in trichomes of the wild tomato species Solanum habrochaites and characterization of trichome-specific 3'/5'-and 7/4'-myricetin O-methyltransferases." *Plant physiology* 155.4 (2011): 1999-2009.
36. LIU, Yu-Bo, et al. "Chemical Constituents of< i> Toona ciliata</i> var.< i> pubescens</i>." *Chinese Journal of Natural Medicines* 9.2 (2011): 115-119.
37. Alarcon-Aguilara, F. J., et al. "Study of the anti-hyperglycemic effect of plants used as antidiabetics." *Journal of Ethnopharmacology* 61.2 (1998): 101-110.
38. Andrade-Cetto, Adolfo, and Michael Heinrich. "Mexican plants with hypoglycaemic effect used in the treatment of diabetes." *Journal of ethnopharmacology* 99.3 (2005): 325-348.
39. Patel, D. K., et al. "Diabetes mellitus: an overview on its pharmacological aspects and reported medicinal plants having antidiabetic activity." *Asian Pacific journal of tropical biomedicine* 2.5 (2012): 411-420.
40. Fatima, Amreen, Parul Agrawal, and Prem Prakash Singh. "Herbal option for diabetes: an overview." *Asian Pacific Journal of Tropical Disease* 2 (2012): S536-S544.

41. Pushpalatha, M., and T. Ananthi. "Protective Effect of Solanum pubescens LINN on CCl₄ Induced Hepatotoxicity in Albino Rats." *Mintage Journal of Pharmaceutical and Medicinal Science* 1.1 (2012): 11-13.
42. Bhattacharyya, J., and Mara Z. de Almeida. "Isolation of the constituents of the root-bark of Guettarda platypoda." *Journal of Natural Products* 48.1 (1985): 148-149.
43. Rahman, Haseeb Ur, et al. "PHYTOCHEMICAL PROFILING OF SUCCESSIVE EXTRACTS OF FRUIT AND STEM BARK OF SOLANUM PUBESCENS." *International Journal of Pharmacy and Pharmaceutical Sciences* 6.9 (2014).
44. Mannan, Md Abdul, et al. "A Quick Review on Anti-diabetic Plants and Action of Phytochemicals." *International Journal* 2.5 (2014): 227-249.
45. Kumari, GN Krishna, L. Jagan Mohan Rao, and NS Prakasa Rao. "Flavonol 3-O-methyl ethers from Solanum pubescens." *Journal of Natural Products* 48.1 (1985): 149-150.
46. Hemamalini, K., and S. B. Sathya. "Hepatoprotective activity of Sophora interrupta and Holoptelea integrifolia against carbontetrachloride induced hepatotoxicity in rats." *International Journal of Biology Pharmacy and Allied Sciences* 2 (2013): 80-89.
47. Peesa, Jaya Preethi. "Herbal medicine for diabetes mellitus: A Review." *International Journal of Phytopharmacy* 3.1 (2013): 01-22.
48. Barbosa-Filho, José M., et al. "Plants and their active constituents from South, Central, and North America with hypoglycemic activity." *Revista Brasileira de Farmacognosia* 15.4 (2005): 392-413.
49. Arivoli, S., and Samuel Tennyson. "Studies on the Mosquitocidal Activity of (L.) Spreng (Rutaceae) Leaf Extracts Against, and (Diptera: Culicidae)." *Journal of Ethnopharmacology* 88.1 (2003): 45-50.